What are HLA-matched cell platforms?

Cell lines are created from patient-derived blood and tumor tissue. Our cell platforms are developed from the same patient and were HLA-typed to ensure they are from the same patient.

WHAT ARE THE ADVANTAGES OF HLA-MATCHED CELLS?

null

HIGHER SPECIFICITY

Higher specificity results in exquisite sensitivity between the TILs and tumors, resulting in an increased ability to detect the impact factors within the tumor microenvironment that could be masked by allogeneic responses.
null

WELL CHARACTERIZED

Highly characterized tumors (e.g. Braf mutations and STR profiles are known). Huge panel from which one can assess the impact of potential drugs.
null

ESTABLISHED DATA WITH APPROVED IMMUNE MODULATORS

Established data with anti-PD1 and anti-PD-L1 drug candidates – good for comparative studies.
null

REPEAT STUDIES ACROSS ASSAY FORMATS

A standardized and reproducible system which with one can assess immune responses across various platforms.
null

BROAD SPECTRUM APPLICATIONS IN CANCER

Leverage the readouts on mechanism and function and extend applications into other tumor types.

WHAT CAN WE STUDY WITH OUR CELL PLATFORMS

There are several studies that can help our partners evaluate phenotypic and functional analysis across various assay formats. The well-characterized nature of our cell platforms enables us to understand the “inputs” and “outputs” in the screening of drug candidates.

HOW DOES IMMUNACCEL SCREEN DRUG CANDIDATES

We work with key opinion leaders in the IO field in designing and developing assays using our cell platforms.

[mc4wp_form id=”200″]